Dimensional Fund Advisors LP Acquires 186,254 Shares of Arvinas, Inc. (NASDAQ:ARVN)

Dimensional Fund Advisors LP lifted its holdings in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 28.3% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 843,430 shares of the company's stock after purchasing an additional 186,254 shares during the period. Dimensional Fund Advisors LP owned 1.23% of Arvinas worth $16,168,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Barclays PLC increased its position in Arvinas by 198.9% in the third quarter. Barclays PLC now owns 121,699 shares of the company's stock worth $2,998,000 after purchasing an additional 80,984 shares during the period. Franklin Resources Inc. increased its holdings in Arvinas by 11.6% in the third quarter. Franklin Resources Inc. now owns 69,190 shares of the company's stock valued at $1,776,000 after purchasing an additional 7,166 shares during the last quarter. Nordea Investment Management AB increased its holdings in Arvinas by 4.1% in the fourth quarter. Nordea Investment Management AB now owns 232,886 shares of the company's stock valued at $4,404,000 after purchasing an additional 9,196 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in Arvinas by 0.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 140,518 shares of the company's stock valued at $2,694,000 after buying an additional 777 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in Arvinas by 228.8% during the fourth quarter. SG Americas Securities LLC now owns 32,424 shares of the company's stock worth $622,000 after buying an additional 22,564 shares during the last quarter. Institutional investors and hedge funds own 95.19% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on ARVN shares. Truist Financial restated a "hold" rating and set a $11.00 price objective (down previously from $21.00) on shares of Arvinas in a report on Monday, May 5th. Wells Fargo & Company lowered their price objective on shares of Arvinas from $26.00 to $19.00 and set an "overweight" rating for the company in a research report on Friday, May 2nd. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arvinas in a report on Friday, February 7th. Citigroup decreased their target price on Arvinas from $10.00 to $9.50 and set a "neutral" rating for the company in a research note on Monday, May 5th. Finally, BTIG Research set a $16.00 price target on Arvinas and gave the stock a "buy" rating in a research report on Friday, May 2nd. Eight research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $20.91.

Arvinas Price Performance

ARVN stock traded down $0.19 during midday trading on Wednesday, hitting $6.10. The company's stock had a trading volume of 840,330 shares, compared to its average volume of 1,304,292. Arvinas, Inc. has a twelve month low of $5.94 and a twelve month high of $37.38. The stock has a market capitalization of $445.46 million, a P/E ratio of -2.20 and a beta of 2.21. The company's fifty day moving average price is $8.20 and its 200 day moving average price is $16.48.

Arvinas (NASDAQ:ARVN - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $1.14 earnings per share for the quarter, topping the consensus estimate of ($0.93) by $2.07. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same quarter last year, the business posted ($0.97) EPS. Arvinas's revenue was up 646.2% compared to the same quarter last year. Equities analysts expect that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Noah Berkowitz sold 8,658 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total value of $74,372.22. Following the completion of the sale, the insider now directly owns 110,023 shares in the company, valued at approximately $945,097.57. The trade was a 7.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO John G. Houston sold 31,338 shares of the business's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.72, for a total value of $523,971.36. Following the completion of the transaction, the chief executive officer now directly owns 1,157,480 shares of the company's stock, valued at approximately $19,353,065.60. This trade represents a 2.64% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 50,230 shares of company stock valued at $769,402 over the last 90 days. 4.73% of the stock is currently owned by insiders.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.